Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Micafungin sodium
Drug ID BADD_D01456
Description Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Indications and Usage For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
Marketing Status Prescription
ATC Code J02AX05
DrugBank ID DB01141
KEGG ID D02465
MeSH ID D000077551
PubChem ID 23666118
TTD Drug ID D06TOE
NDC Product Code 75924-308; 0143-9362; 0469-3250; 0143-9361; 58623-0113; 68254-0012; 62227-005; 66529-0005; 25021-191; 70594-037; 63126-908; 69766-090; 63323-728; 63323-729; 25021-190; 53296-0114; 65727-055; 70594-036; 0469-3211; 16436-0114
Synonyms Micafungin | FK 463 | FK463 | FK-463 | Micafungin Sodium | Mycamine
Chemical Information
Molecular Formula C56H70N9NaO23S
CAS Registry Number 208538-73-2
SMILES CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC (=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)[O-])O)O) C(CC(=O)N)O)C)O)O)O.[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Neutropenia01.02.03.004--Not Available
Pancytopenia01.03.03.003--Not Available
Pericardial effusion02.06.01.002--
Phlebitis24.05.03.001; 12.02.01.002--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Swelling face23.04.01.018; 10.01.05.018--Not Available
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombotic thrombocytopenic purpura24.07.06.014; 23.06.01.011; 01.08.01.005--
Toxic epidermal necrolysis11.07.01.006; 10.01.01.006; 23.03.01.008; 12.03.01.015--
Urticaria23.04.02.001; 10.01.06.001--
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Vomiting07.01.07.003--
Infusion related reaction08.01.03.002; 12.02.05.009; 10.01.01.017--
Blood alkaline phosphatase increased13.04.02.004--
Urine output decreased13.13.03.001--
Renal impairment20.01.03.010--Not Available
The 2th Page    First    Pre   2    Total 2 Pages